In order to evaluate whether peripheral and/or cardiac α-adrenoceptors were involved in the cardiac effects of sympathomimetic drugs, the effects of phenoxybenzamine (1 mg/kg body weight) on increasing, graded doses of dobutamine, etilefrine and xylometazoline were investigated in anesthetized dogs. Measurements were made of simultaneous changes in left ventricular pressure, rate of rise of left ventricular pressure (dP/dt), aortic blood pressure, peripheral blood flow as well as heart rate. To determine the actual contractile responses independent of hemodynamic influences on the myocardium, all drugs were studied under conditions of fixed mean aortic pressure and heart rate. Dobutamine produced increases in dP/dtmax which remained unaffected by phenoxybenzamine, whereas the blood pressure increase was antagonized. The contractile responses, however, were less pronounced under fixed blood pressure conditions demonstrating that part of the inotropic response to dobutamine is attributable to an α-receptor-mediated increase of the afterload. The primary effect on myocardium is assumed to be mediated by β1-receptors. In contrast to conditions of uncontrolled hemodynamics, etilefrine produced only small increases in contractility. Since these effects were antagonized by phenoxybenzamine and phentolamine (0.5 mg/kg body weight), it can be postulated that the canine heart contains a population of adrenergic α-receptors. However, a further subtype of α-receptor must exist, since xylometazoline produced negative inotropic responses which were prevented by phenoxybenzamine and were even potentiated when α-receptor-mediated increase of the afterload was eliminated by fixing the blood pressure. Apart from α-receptors situated in the myocardium, the sinus node must also contain both receptor subtypes since the positive chronotropic response to etilefrine as well as the negative chronotropic response to xylometazoline were inhibited by phenoxybenzamine.

Keywords:
Dobutarmne, Etilefrine, Xylometazoline, Dogs, Controlled and uncontrolled hemodynamics, α-Receptor subtypes
This content is only available via PDF.
© 1981 S. Karger AG, Basel
1981
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.